Anticancer drug targets: approaching angiogenesis
Open Access
- 1 December 1999
- journal article
- review article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 104 (11), 1497-1501
- https://doi.org/10.1172/jci8849
Abstract
No abstract availableThis publication has 28 references indexed in Scilit:
- Synthetic peptides define critical contacts between elongin C, elongin B, and the von Hippel-Lindau proteinJournal of Clinical Investigation, 1999
- Vascular Channel Formation by Human Melanoma Cells in Vivo and in Vitro: Vasculogenic MimicryThe American Journal of Pathology, 1999
- Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGFScience, 1999
- Effects of Angiogenesis Inhibitors on Multistage Carcinogenesis in MiceScience, 1999
- Reciprocal paracrine interactions between tumour cells and endothelial cells: the ‘angiogenesis progression’ hypothesisEuropean Journal Of Cancer, 1996
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Organ targeting In vivo using phage display peptide librariesNature, 1996
- Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a lewis lung carcinomaCell, 1994
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971